The United Kingdom: Biolog-id and Nicholson Consulting Ltd Cooperate to Develop a Demonstration Lab to Showcase Biolog Transfusion Solution
Biolog-id, a global service provider of connected healthcare solutions, and Nicholson Consulting Ltd, an innovative consulting and engineering company specialized in the blood transfusion field, join their forces to set up a demonstration lab located at Malvern Hills Science Park, in the south of Birmingham. This co-branded demo environment will showcase to the UK market the biolog-id’s cutting-edge product-line: Biolog Transfusion Solution.
Based on the RFID technology, Biolog Transfusion Solution has been designed to respond to the needs of all the actors involved along the blood transfusion supply chain. By combining software, equipment and tags, this breakthrough innovation offers to manage in real-time each application area, from collection and manufacturing at the blood centre, central and remote inventory at the blood banks to blood compound administration at patient’s bedside.
Flexible and reliable, the biolog-id technology generates value throughout the lifecycle of blood products to help healthcare professionals better drive their operations. Benefits that customers will be able to discover from the opening of the showroom, scheduled for early June.
“We are very pleased to collaborate with biolog-id to successfully implement this project. This demonstration lab will be a real asset for our potential customers: this will not only allow them to see Biolog Transfusion Solution in real-world but also experiment and handle it”, declares Gordon Nicholson, Managing Director at Nicholson Consulting Ltd.
“Beyond presenting our solutions, this demonstration laboratory will allow us to test and validate new equipment aimed at strengthening our offer. We have full confidence in our local partner who will be able to effectively manage this innovation facility, the first for biolog-id”, says Philippe Jacquet, Executive Director of Sales EMEA/LATAM at biolog-id.
Present in 14 countries all over the world, biolog-id continues its development over the Channel with the implementation of this new demonstration laboratory. In the United Kingdom, the Biolog Transfusion Solution has already been adopted by the Scottish National Blood Transfusion Service (SNBTS) to efficiently manage the supply of blood products to different remote centres and communities.
About biolog-id:
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products: blood products (red blood cells, platelets, plasma), chemotherapies, parenteral nutrition.
The information generated by biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions and ultimately the safety of the therapeutics administered to patients.
Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India, and Asia Pacific. Biolog-id is owned by its founder, managers, and the Xerys Funds. Xerys Gestion is a French investment company primarily positioned on trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech and new digital technologies.
Company URL: www.biolog-id.com
About Nicholson Consulting Ltd:
Nicholson Consulting Ltd is a SME innovation company working in the specialist field of blood component production and in the design of blood collection systems both for human and animal transfusion. The company is based in the Malvern Hills Science Park and the staff have a combined experience of over 50 years working in Blood Transfusion Service and hospital haematology laboratories. More recently the company has been in a collaboration with a major blood pack supplier to assist in their R&D and product validation programmes.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005757/en/
Contact information
Astrid Billard, astrid.billard@biolog-id.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Transition Industries and Mitsubishi Gas Chemical Sign Agreement for the Purchase and Sale of Ultra-Low Carbon Methanol6.11.2025 06:00:00 EET | Press release
Transition Industries LLC, a developer of world-scale, net-zero carbon emissions methanol and hydrogen projects, signed a long-term methanol sales and purchase agreement with Mitsubishi Gas Chemical Company, Inc. (MGC) for the offtake of ultra-low carbon methanol. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105695992/en/ Masahiko Naito, Division Director of Mitsubishi Gas Chemical and Rommel Gallo, CEO of Transition Industries sign agreement in Tokyo, November 6, 2025 Under the Agreement, which will become effective upon the Project’s Final Investment Decision (FID), Transition Industries will supply MGC approximately 1 million MT per annum of ultra-low carbon methanol from its Pacifico Mexinol project, a 6,130 MT per day methanol production facility near Topolobampo, Sinaloa, Mexico, expected to be in operation in 2029. Transition Industries is jointly developing Pacifico Mexinol with the International Finance Corpora
Kinaxis Announces Normal Course Issuer Bid6.11.2025 00:00:00 EET | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) is pleased to announce that the Toronto Stock Exchange (the “TSX”) has accepted a notice (the “Notice”) filed by the Company of its intention to make a normal course issuer bid (the “NCIB”). In connection with the NCIB, the Company has entered into an automatic share purchase plan (an “ASPP”) with its designated broker to allow for purchases of its common shares (the “Shares”). The Notice provides that the Company may, during the 12-month period commencing November 12, 2025 and ending November 11, 2026, or on such earlier date as Kinaxis completes its purchases or provides notice of termination, purchase up to 1,403,042 Shares in total, representing approximately 5% of the issued and outstanding Shares as at October 31, 2025. As of the close of business on October 31, 2025, the Company had 28,060,844 Shares issued and outstanding. Except for block purchases permitted under the rules of the TSX, the number of Shares to be purchased p
Hyper ® Wins Dual CES 2026 Innovation Awards ® for its Breakthrough Tech Accessories5.11.2025 23:50:00 EET | Press release
Hyper®, a leader in mobile tech accessories for creators and power users, today announced it has been honored with two CES2026 Innovation Awards® in the Consumer Peripherals and Accessories category. These awards reflect Hyper’s mission to build breakthrough solutions that help users create, connect, and go beyond the limits of their devices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105297377/en/ CES Innovation Awards® 2026 Honorees: HyperSpace™ Trackpad Pro and HyperDrive® Next redefine haptics, personalization, and next-gen USB4 V2 speed. The CES Innovation Awards program is an annual competition that honors the most innovative, new products in consumer technology, recognizing top innovations across multiple categories. “For 20 years, Hyper has led the tech accessory space with industry-defining ‘world’s firsts’ in power, connectivity, mobility, and desktop solutions,” said Gabi Iorio, Director of Global Marketing
CWAN Reports 800+ AI Agents Now Available for Deployment Across $10 Trillion in Client Assets5.11.2025 23:15:00 EET | Press release
Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, today announced the global deployment of CWAN GenAI, a newly-launched, embedded generative AI platform that can be deployed to transform investment management, risk management, reporting and operations across more than $10 trillion in institutional assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105092732/en/ What sets CWAN GenAI apart from the experimental AI tools flooding the market is its production-ready integration. Unlike copilots or chat tools layered onto legacy systems, CWAN GenAI is fully integrated and deployed into production on CWAN’s front-to-back platform, enabling clients to work alongside AI as collaborative partners in their investment operations. The platform currently supports 800+ AI agents created by CWAN clients and internal teams, plus 20 highly trained domain-specific agents. These agen
IonQ and Swiss Consortium Launch First Citywide Dedicated Quantum Network in Geneva5.11.2025 23:04:00 EET | Press release
IonQ (NYSE: IONQ), the world’s leading quantum company, with luminary Swiss partners, successfully deployed a citywide quantum network in Geneva, Switzerland. This consortium of world-class academic, enterprise, and public institutions will advance quantum cybersecurity and communications research, collaboration, and innovation. The new infrastructure, named the Geneva Quantum Network (GQN), is the nation’s first dedicated quantum network connecting key institutions across the region. “Our involvement in the GQN alongside globally-renowned companies such as Rolex and research leaders like CERN, underscores our IP and pioneering leadership in quantum cybersecurity and communication,” said Niccolo de Masi, Chairman and CEO of IonQ. “IonQ is leveraging existing fiber optic infrastructure to link partners across the Geneva region. Our partnership with leading universities, government, and industry players in Geneva is enabling real-world quantum communications, accelerating research, and b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom